StockpollyBeta
Get App
Delisting riskPopularity #4,213
CELZ · NASDAQ · Biotechnology

Creative Medical Technology (CELZ)

Develops regenerative cell therapies for pain and diabetes alongside physician-use procedure kits.

$0.9120
After hours−0.01 (−0.87%)
At close$0.9200(−8.46%)

  1. Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing

    GlobeNewsWire

  2. Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning

    GlobeNewsWireClinical

  3. Creative Medical Technology Stock Surges After Key Patent Win

    Benzinga

  4. Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

    GlobeNewsWire

  5. Creative Medical Technology Holdings Issues Mid-Year Update

    GlobeNewsWire

  6. Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds

    GlobeNewsWire

  7. Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain

    GlobeNewsWire

  8. Creative Medical Technology opens nationwide burn-pit data registry

    Proactive Investors

  9. Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

    GlobeNewsWire

  10. Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies

    GlobeNewsWire

  11. Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

    GlobeNewsWire

  12. Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative

    GlobeNewsWire

  13. Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

    GlobeNewsWire

  14. Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now

    Zacks Investment Research

  15. Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

    GlobeNewsWire

  16. Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

    GlobeNewsWire

  17. Creative Medical Technology Holdings Issues Letter to Shareholders

    GlobeNewsWire

  18. Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

    GlobeNewsWire

  19. New Strong Sell Stocks for July 31st

    Zacks Investment Research

  20. Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

    GlobeNewsWire